Ady Azhari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ady Azhari has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Amal Jamjoom
Department of Periodontology, King Abdulaziz University, Jeddah, Saudi Arabia
1 shared publication - Arwa A. Banjar
Department of Periodontics, Faculty of Dentistry King Abdulaziz University Jeddah Saudi Arabia
1 shared publication - Arwa Badahdah
Department of Periodontology, Faculty of Dentistry, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
1 shared publication - Badr Othman
Department of Periodontics, Faculty of Dentistry, King AbdulAziz University, Jeddah, Saudi Arabia
1 shared publication - Basel Sharabi
Department of Periodontology, King Abdulaziz University, Jeddah, Saudi Arabia
1 shared publication - Bashar Abdulhakem Abu Nawas
Faculty of Medicine, Mutah University, Al-Karak, Jordan
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in The Saudi Dental Journal
- Vol. 38 (5) , 58
Hyaluronic acid versus microneedling with injectable platelet-rich fibrin in the treatment of partial loss of interdental papillae: A pilot randomized clinical trial
Loss of the interdental papilla represents a frequent aesthetic and functional challenge in dentistry. Traditional surgical procedures can partially restore papillary form but are limited by technical sensitivity, donor-site morbidity, and unpredictable long-term results. Consequently, interest has shifted toward minimally invasive, biologically driven strategies for papilla reconstruction. Among non-surgical options, the injection of hyaluronic acid (HA) and the injectable form of platelet-rich fibrin (iPRF) have shown considerable promise. Combining microneedling (MN) enhances trans-mucosal delivery of the biologic agent and can boost regenerative outcomes. Despite promising results, direct comparisons between HA and MN + iPRF remain scarce. Therefore, the present study aims to compare the clinical outcomes of MN + iPRF versus HA gel injection in the reconstruction of Class I interdental papilla loss. This pilot study was conducted as a split-mouth, double-blind, randomized trial to compare the efficacy of MN + iPRF vs. HA injections in reconstructing interdental papillae. A total of seven adult patients (N = 7) were enrolled, contributing 20 interdental papillary sites based on individual clinical presentation. Each site was randomly assigned to one of two treatment groups: Group MN + iPRF (n = 10 sites), and Group HA (n = 10 sites). Clinical parameters measured at baseline, 6 weeks, and 12 weeks included papillary height and papillary width at three levels (base, middle, and tip), and Papillary thickness. Both techniques showed comparable improvements in papillae height and contour over the study period. Intergroup analysis showed no statistically significant difference in all parameters at any time point. This pilot study, with its small sample size, suggests comparable short-term outcomes, but larger studies are needed to determine definitive efficacy. The absence of statistical significance should therefore be interpreted cautiously and does not indicate equivalence between the two treatment approaches.
- 29 April 2026
- Published by Springer Nature in The Saudi Dental Journal
- Vol. 38 (5) , 58
Open AccessHyaluronic acid versus microneedling with injectable platelet-rich fibrin in the treatment of partial loss of interdental papillae: A pilot randomized clinical trial
Loss of the interdental papilla represents a frequent aesthetic and functional challenge in dentistry. Traditional surgical procedures can partially restore papillary form but are limited by technical sensitivity, donor-site morbidity, and unpredictable long-term results. Consequently, interest has shifted toward minimally invasive, biologically driven strategies for papilla reconstruction. Among non-surgical options, the injection of hyaluronic acid (HA) and the injectable form of platelet-rich fibrin (iPRF) have shown considerable promise. Combining microneedling (MN) enhances trans-mucosal delivery of the biologic agent and can boost regenerative outcomes. Despite promising results, direct comparisons between HA and MN + iPRF remain scarce. Therefore, the present study aims to compare the clinical outcomes of MN + iPRF versus HA gel injection in the reconstruction of Class I interdental papilla loss. This pilot study was conducted as a split-mouth, double-blind, randomized trial to compare the efficacy of MN + iPRF vs. HA injections in reconstructing interdental papillae. A total of seven adult patients (N = 7) were enrolled, contributing 20 interdental papillary sites based on individual clinical presentation. Each site was randomly assigned to one of two treatment groups: Group MN + iPRF (n = 10 sites), and Group HA (n = 10 sites). Clinical parameters measured at baseline, 6 weeks, and 12 weeks included papillary height and papillary width at three levels (base, middle, and tip), and Papillary thickness. Both techniques showed comparable improvements in papillae height and contour over the study period. Intergroup analysis showed no statistically significant difference in all parameters at any time point. This pilot study, with its small sample size, suggests comparable short-term outcomes, but larger studies are needed to determine definitive efficacy. The absence of statistical significance should therefore be interpreted cautiously and does not indicate equivalence between the two treatment approaches.
- 22 March 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (9) , 1-21
Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability
Lung cancer is the most prevalent cancer and cause of death; most patients present themselves at an advanced stage and continuously acquire resistance to targeted agents, antibody–drug conjugates, chemotherapy, and immune checkpoint inhibitors. In addition to secondary mutations, epigenetically driven cellular plasticity, including DNA methylation, histone modification, chromatin remodeling, RNA (m 6A)-marks, and non-coding RNAs, facilitates resistance coordination, EMT/drug-tolerant persisters, lineage switching (e.g., NSCLC to NSCLC), bypass signaling, and immune evasion by tumor cells. These states can be therapeutically rewired by epigenetic drugs: low-dose DNMT/HDAC priming restores silenced tumor-suppressor and antigen-presentation genes and activates viral-mimicry interferon signaling to augment checkpoint blockade; EZH2 and LSD1 inhibitors target plasticity and neuroendocrine programs; BET inhibition suppresses adaptive transcription; CBP/p300 modulators suppress NRF2-dependent redox survival; Combination therapies exploiting synthetic lethality through PRMT5 inhibition, applied rationally with TKIs, ICIs, chemotherapy, and antibody–drug conjugates (ADCs), are currently under clinical investigation. Biomarker-directed patient selection (e.g., MTAP loss clustering, EZH2/LSD1 activity, methylation and chromatin signatures, and liquid biopsy dynamics of methylation or ctDNA) will be critical to enrich for patients most likely to benefit. In the future, better optimized sequencing using short priming windows, intermittent dosing, and future readouts of prospective pharmacodynamics could transform transient re-sensitization into lasting control. This study aims to critically appraise mechanistic and clinical evidence linking epigenetic plasticity to therapy resistance in advanced lung cancer and to propose biomarker-directed epigenetic combination and sequencing strategies to restore drug sensitivity.
- 22 March 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (9) , 1-21
Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability
Lung cancer is the most prevalent cancer and cause of death; most patients present themselves at an advanced stage and continuously acquire resistance to targeted agents, antibody–drug conjugates, chemotherapy, and immune checkpoint inhibitors. In addition to secondary mutations, epigenetically driven cellular plasticity, including DNA methylation, histone modification, chromatin remodeling, RNA (m 6A)-marks, and non-coding RNAs, facilitates resistance coordination, EMT/drug-tolerant persisters, lineage switching (e.g., NSCLC to NSCLC), bypass signaling, and immune evasion by tumor cells. These states can be therapeutically rewired by epigenetic drugs: low-dose DNMT/HDAC priming restores silenced tumor-suppressor and antigen-presentation genes and activates viral-mimicry interferon signaling to augment checkpoint blockade; EZH2 and LSD1 inhibitors target plasticity and neuroendocrine programs; BET inhibition suppresses adaptive transcription; CBP/p300 modulators suppress NRF2-dependent redox survival; Combination therapies exploiting synthetic lethality through PRMT5 inhibition, applied rationally with TKIs, ICIs, chemotherapy, and antibody–drug conjugates (ADCs), are currently under clinical investigation. Biomarker-directed patient selection (e.g., MTAP loss clustering, EZH2/LSD1 activity, methylation and chromatin signatures, and liquid biopsy dynamics of methylation or ctDNA) will be critical to enrich for patients most likely to benefit. In the future, better optimized sequencing using short priming windows, intermittent dosing, and future readouts of prospective pharmacodynamics could transform transient re-sensitization into lasting control. This study aims to critically appraise mechanistic and clinical evidence linking epigenetic plasticity to therapy resistance in advanced lung cancer and to propose biomarker-directed epigenetic combination and sequencing strategies to restore drug sensitivity.
- Open Access
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Dental Medicine
- Vol. 7
Accuracy of artificial intelligence applications in periodontics: a thematic narrative review
Background: Artificial intelligence (AI) has been increasingly applied to periodontal diagnostics across periapical, bitewing, panoramic radiographs, cone-beam computed tomography (CBCT), and intraoral photographs. Recent multicenter, external validation, and explainability-focused studies have advanced the field, yet variability in datasets, anatomical sites, reference standards, model architectures, and reporting practices introduces significant heterogeneity. A structured synthesis of current evidence is therefore warranted. Main text: This review synthesizes 35 studies published between 2019 and 2025, evaluating AI applications in four diagnostic domains: detection of periodontal bone loss, measurement of alveolar bone levels, identification of furcation involvement, and detection of periapical lesions. Convolutional neural network (CNN)-based models using periapical radiographs achieved moderate-to-high diagnostic accuracy (0.82–0.85) and AUCs above 0.88, comparable to clinician performance. Panoramic radiographs yielded lower sensitivity and specificity than CBCT, where deep learning systems reached higher accuracy (up to 0.91) and superior volumetric assessment. Intraoral photographic analyses showed variable performance (0.46–1.00), largely due to inconsistent imaging and reference standards. Emerging trends include hybrid segmentation–classification architectures, transformer-based networks, and clinician-in-the-loop approaches. Determinants of performance encompass reference standard quality, dataset diversity, anatomical complexity, and adherence to STARD-AI and TRIPOD-AI reporting frameworks. Conclusions: AI demonstrates clinically relevant diagnostic accuracy in periodontal imaging, especially for measurement standardization and decision support. Although autonomous diagnosis remains premature, integrating explainable, externally validated AI systems within clinician-guided workflows supported by standardized reporting offers a practical route toward clinical translation.
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Dental Medicine
- Vol. 7
Open AccessAccuracy of artificial intelligence applications in periodontics: a thematic narrative review
Background: Artificial intelligence (AI) has been increasingly applied to periodontal diagnostics across periapical, bitewing, panoramic radiographs, cone-beam computed tomography (CBCT), and intraoral photographs. Recent multicenter, external validation, and explainability-focused studies have advanced the field, yet variability in datasets, anatomical sites, reference standards, model architectures, and reporting practices introduces significant heterogeneity. A structured synthesis of current evidence is therefore warranted. Main text: This review synthesizes 35 studies published between 2019 and 2025, evaluating AI applications in four diagnostic domains: detection of periodontal bone loss, measurement of alveolar bone levels, identification of furcation involvement, and detection of periapical lesions. Convolutional neural network (CNN)-based models using periapical radiographs achieved moderate-to-high diagnostic accuracy (0.82–0.85) and AUCs above 0.88, comparable to clinician performance. Panoramic radiographs yielded lower sensitivity and specificity than CBCT, where deep learning systems reached higher accuracy (up to 0.91) and superior volumetric assessment. Intraoral photographic analyses showed variable performance (0.46–1.00), largely due to inconsistent imaging and reference standards. Emerging trends include hybrid segmentation–classification architectures, transformer-based networks, and clinician-in-the-loop approaches. Determinants of performance encompass reference standard quality, dataset diversity, anatomical complexity, and adherence to STARD-AI and TRIPOD-AI reporting frameworks. Conclusions: AI demonstrates clinically relevant diagnostic accuracy in periodontal imaging, especially for measurement standardization and decision support. Although autonomous diagnosis remains premature, integrating explainable, externally validated AI systems within clinician-guided workflows supported by standardized reporting offers a practical route toward clinical translation.